The specifics, since they change the answer: 97.6% · PeptideMeter · 97.1%.
An unexpected observation, and I would like a differential rather than reassurance.
The conditions were within what I understood to be the acceptable range, which is why I am asking.
What is the differential here, and which test discriminates between the options?
Put another way, understanding purity requires separating the chemistry from the method from the reporting convention, and the three are not independent.
Sample solvent strength affects peak shape — if you inject in strong solvent on a gradient starting in weak solvent, the solvent peak can distort your main peak or create a false shoulder.
Detection wavelength matters because 214 nm sees the peptide backbone while 280 nm sees only aromatic side chains — so truncation impurities lacking a tryptophan are invisible at 280 nm.
The Arrhenius relationship for peptide degradation is the basis of accelerated stability testing and also governs how quickly methods drift with temperature.
Worth noting that method standardisation is poor in the research-grade space compared to pharmaceutical work, so identical-looking methods can produce different results.
If you are ranking vendors, specify a method and have all samples tested at the same place.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsRead the chromatogram before you read the number, because the number without the trace is not a measurement, it is a claim.
Retention time is sequence-specific and method-specific, so comparing your result to a supplier value using a different method is meaningless without method documentation.
Mechanically, buffer versus acid in the mobile phase changes the ionisation state of basic and acidic residues, shifting retention and selectivity — same vial, potentially different separation.
I would be careful about over-reading a single measurement — treat it as a data point, not as ground truth.
Compare purity within a single laboratory on the same method, never across laboratories.
Specifically, purity is a method-dependent figure, and that is not a limitation of the measurement, it is a property of what the measurement actually answers.
Tailing factor measures peak shape, and a badly tailing peak spreads into the region where small impurities live, forcing tangent-skim integration that assigns tail area to the main peak.
Column pore size affects mass transfer — a 100 Angstrom packing on a 5 kDa peptide restricts diffusion, broadening the peak and potentially hiding small impurities in the shoulders.
Proline conformer interconversion kinetics are well-characterised and the half-life is of the same order as the chromatographic peak width at room temperature.
The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.
edited 9 Nov 2025 by Dr_Lena_Ostrowska — added the method parameters
Area percentage is not mass percentage, and conflating the two is the most common misreading of a purity figure.
Mobile phase additive choice affects ionisation and peak shape — TFA gives sharp peaks but suppresses mass spectrometry signal, formic acid gives worse peaks but preserves signal.
Published side-by-side method comparisons show that a two-point difference in purity on the same vial is easily explained by method choice alone.
The caveat is that purity without identity is only half an answer — a high purity does not mean the peak is actually what you think it is.
If you are ranking vendors, specify a method and have all samples tested at the same place.
The short answer is that two competent laboratories on identical material will disagree, and the disagreement is almost always explainable by method differences.
Mass on column affects detector linearity and peak overlap — overloading broadens peaks and hides neighbours, while underloading improves resolution but loses sensitivity.
The ICH Q3A impurity thresholds and the relevant pharmacopoeial chapters all specify method validation requirements that almost no research-grade certificate claims to meet.
The limitation is that single-digit micro-impurities become invisible at typical reporting thresholds, so "no impurities detected" means "none above one in two thousand."
Compare purity within a single laboratory on the same method, never across laboratories.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.